Last updated: August 1, 2026
Penicillin G benzathine remains the standard injectable treatment for syphilis and a major tool for rheumatic fever prevention. Penicillin G procaine has a narrower role because it requires more frequent dosing and is less convenient for outpatient treatment. Both products are mature, off-patent medicines, but manufacturing complexity, limited suppliers, injectable-product quality controls and recurring shortages create commercial barriers that are more significant than patent barriers.
The strongest demand outlook is for benzathine penicillin G, driven by rising syphilis incidence, congenital syphilis prevention, public-health procurement and recurrent supply constraints. Procaine penicillin G is likely to remain a smaller, regional market concentrated in settings where benzathine supply is limited or where clinicians use procaine-containing regimens.
What are penicillin G benzathine and penicillin G procaine used for?
Penicillin G benzathine is a long-acting intramuscular formulation of penicillin G. The drug forms a depot at the injection site and releases penicillin slowly over time.
Penicillin G procaine combines penicillin G with procaine to slow absorption and reduce injection discomfort. It has a shorter duration of action than benzathine penicillin G and usually requires repeated daily administration.
| Product |
Primary active ingredient |
Typical clinical role |
Administration profile |
Commercial position |
| Bicillin L-A |
Penicillin G benzathine |
Syphilis, yaws, rheumatic fever prophylaxis, selected streptococcal infections |
Deep intramuscular injection; dosing depends on indication |
Principal U.S. branded product |
| Bicillin C-R |
Penicillin G benzathine plus penicillin G procaine |
Selected streptococcal infections |
Intramuscular injection |
Separate product; not interchangeable with Bicillin L-A for syphilis |
| Penicillin G procaine injection |
Penicillin G procaine |
Selected bacterial infections where daily parenteral penicillin is appropriate |
Repeated intramuscular injections |
Smaller and more fragmented market |
Bicillin C-R must not be substituted for Bicillin L-A in the treatment of syphilis because the benzathine dose and pharmacokinetic profile differ. The Centers for Disease Control and Prevention specifically recommends benzathine penicillin G for recommended syphilis regimens (CDC, 2021).
What is the FDA regulatory status of penicillin G benzathine?
Bicillin L-A is an FDA-approved prescription injectable product marketed by Pfizer. The product is approved for intramuscular use and is supplied in prefilled syringes and other presentations depending on market availability.
FDA labeling identifies benzathine penicillin G for:
- Primary, secondary and latent syphilis;
- Congenital syphilis-related treatment settings;
- Rheumatic fever and rheumatic heart disease prophylaxis;
- Selected respiratory, skin and soft-tissue infections caused by susceptible organisms.
Penicillin G benzathine is not administered intravenously. Accidental intravenous administration can cause severe or fatal events, which is a central labeling and safety issue.
Penicillin G procaine products have older FDA approvals and historically have been marketed under several brand and generic names. Product availability is more variable than for benzathine penicillin G. FDA approval status must be assessed by individual National Drug Code, application and manufacturer because supply status changes across manufacturers and presentations.
What is the Orange Book status of Bicillin L-A?
Bicillin L-A is an old small-molecule injectable product. Its commercial position does not depend on a conventional blocking patent estate. The principal barriers are manufacturing scale, sterile injectable controls, product-specific formulation know-how and the limited number of qualified suppliers.
The FDA Orange Book should be checked by application number and product presentation for current patent and exclusivity listings. Based on the mature age of penicillin G benzathine products, meaningful unexpired composition-of-matter exclusivity is not expected. The practical U.S. market protection is supply-based rather than patent-based.
When does penicillin G benzathine lose exclusivity?
Penicillin G benzathine lost conventional exclusivity many years ago. The active ingredient was developed and commercialized decades before the modern Hatch-Waxman framework.
| Exclusivity category |
Current assessment |
| New chemical entity exclusivity |
Expired |
| Composition-of-matter patent |
Expired or not commercially relevant |
| Pediatric exclusivity |
No current protection expected |
| Orphan-drug exclusivity |
Not the principal basis of market protection |
| Formulation patent protection |
No known commercially significant blocking estate |
| Method-of-use patents |
Any historical rights are expired or do not block the core market |
| Trademark protection |
Brand names such as Bicillin remain protectable |
| Regulatory exclusivity |
No current exclusivity expected to block an ANDA solely on regulatory grounds |
The absence of meaningful patent protection does not guarantee rapid generic entry. Injectable penicillins require validated sterile manufacturing, container-closure controls, particulate testing, stability data and reliable active-pharmaceutical-ingredient supply.
How many patents cover penicillin G benzathine and penicillin G procaine?
The core medicines are not protected by a significant modern patent estate.
Formulation patents
The principal technical value lies in the depot formulations and manufacturing process. Relevant know-how may include:
- Particle-size control;
- Suspension homogeneity;
- Syringeability;
- Sedimentation behavior;
- Sterility assurance;
- Preservative and excipient control;
- Long-term stability;
- Container-closure compatibility;
- Cold-chain or controlled-storage procedures.
These characteristics can make an abbreviated application operationally difficult even where no enforceable patent blocks approval.
Method-of-use patents
Syphilis treatment, rheumatic fever prophylaxis and treatment of susceptible streptococcal infections are established uses. These indications are generally too old to support active, commercially significant method-of-use patent protection.
Are there Paragraph IV challenges to Bicillin L-A?
No major current Paragraph IV litigation is associated with a patent-centered defense of the core Bicillin L-A market. That outcome follows from the age of the active ingredient and the limited relevance of modern patent exclusivity.
A future ANDA applicant would more likely face:
- Manufacturing and facility requirements;
- Reference-product characterization challenges;
- Suspension formulation development;
- Supply-chain qualification;
- FDA inspection and deficiency-response risk;
- Commercial risk from a small, shortage-sensitive market.
The absence of major patent litigation lowers legal entry risk but does not eliminate development risk.
What clinical trials are evaluating penicillin G benzathine?
The contemporary clinical-trial agenda is concentrated on dosing, treatment effectiveness, pregnancy, congenital syphilis prevention and delivery-system improvement rather than discovery of a new mechanism.
Syphilis dosing and treatment duration
Studies have examined whether one dose of benzathine penicillin G is sufficient for early syphilis in specific populations and whether additional doses improve outcomes. CDC guidelines continue to distinguish early syphilis from late latent syphilis and recommend different dosing schedules based on disease stage (CDC, 2021).
Syphilis in pregnancy
Benzathine penicillin G remains the recommended treatment for syphilis during pregnancy. Clinical research has focused on:
- Whether standard dosing achieves adequate maternal and fetal exposure;
- The impact of obesity and altered pharmacokinetics;
- The role of a second dose in early syphilis;
- Prevention of congenital syphilis;
- Treatment completion and adverse-event monitoring.
The product has no accepted therapeutic substitute for preventing congenital syphilis when penicillin treatment is indicated.
Rheumatic fever prevention
Long-acting benzathine penicillin G is used for secondary prevention of acute rheumatic fever and rheumatic heart disease. Research has focused on adherence, dosing intervals, injection pain, access and alternative delivery approaches.
The World Health Organization recommends secondary prophylaxis with penicillin for eligible patients at risk of recurrent rheumatic fever (World Health Organization, 2024).
Supply and delivery studies
Public-health and academic groups have evaluated ways to reduce missed doses caused by shortages, painful injections, cold-chain requirements and limited clinic access. These studies are commercially important because a more convenient injectable or sustained-release product could compete on delivery performance rather than molecular novelty.
What clinical-trial evidence supports penicillin G procaine?
Penicillin G procaine has a smaller contemporary trial base. Its clinical use is supported mainly by long-standing evidence, regulatory labeling, microbiology and guideline history rather than by a large pipeline of new randomized trials.
Its main limitations are:
- Shorter duration than benzathine penicillin G;
- Need for repeated injections;
- Greater logistical burden;
- Less suitability for single-visit public-health treatment;
- Risk of confusion with benzathine-containing products;
- Variable supply and manufacturer availability.
Procaine penicillin G remains relevant where benzathine penicillin G is unavailable or where local treatment protocols specify daily intramuscular dosing. It is not a direct therapeutic substitute for every benzathine indication.
How large is the penicillin G benzathine market?
The market is difficult to measure through public company reporting because sales are generally included within broader hospital injectables, anti-infectives or established medicines categories.
A practical market model separates demand into four segments:
| Segment |
Demand driver |
Outlook through 2030 |
| Syphilis treatment |
Rising incidence and screening |
High growth |
| Congenital syphilis prevention |
Maternal screening and treatment access |
High public-health priority |
| Rheumatic fever prophylaxis |
Long-term recurring injections |
Stable to moderate growth |
| Other bacterial infections |
Mature and price-sensitive use |
Flat or declining |
Global syphilis cases among adults aged 15 to 49 increased materially during the last decade, supporting demand for benzathine penicillin G (World Health Organization, 2024). In the United States, reported primary and secondary syphilis cases and congenital syphilis cases have also risen, increasing procurement pressure (CDC, 2024).
Market projection, 2025-2030
A reasonable base-case projection is:
| Scenario |
Estimated annual market growth |
2030 market direction |
| Low case |
2% to 4% |
Modest expansion |
| Base case |
5% to 8% |
Meaningful growth led by syphilis |
| High case |
9% to 12% |
Strong expansion if shortages persist and screening improves |
The base case assumes continued syphilis incidence, stable rheumatic fever prophylaxis demand and no rapid replacement by a new long-acting penicillin product. Growth is likely to be stronger in units and public-health volume than in price because pricing pressure remains high for an old antibiotic.
Penicillin G procaine is likely to grow more slowly than benzathine penicillin G. Its projected market trajectory is approximately flat to low single-digit growth, with regional spikes during benzathine shortages.
What companies manufacture or supply these products?
Pfizer has historically been the key U.S. supplier of Bicillin products. The U.S. market has experienced repeated shortages and constrained allocation, making Pfizer’s production capacity strategically important.
Other suppliers may market penicillin G procaine or benzathine products in specific countries. The competitive landscape varies substantially by jurisdiction because:
- Products may be approved under different brand names;
- Some countries use public tenders rather than retail distribution;
- Manufacturer qualification differs by health authority;
- Product presentations and concentrations are not uniform;
- A supplier in one region may not be authorized in another.
The commercial market is therefore concentrated at the manufacturing level even when multiple registrations exist.
What patent litigation and settlement agreements affect these drugs?
No major active patent litigation or settlement structure is known to determine the core U.S. market for penicillin G benzathine or penicillin G procaine. The products are too old for a typical branded-drug patent settlement to be the main market variable.
The more relevant disputes and regulatory risks concern:
- Product shortages;
- Allocation practices;
- Quality investigations;
- Manufacturing-site changes;
- Labeling and medication-error prevention;
- Contracting and public procurement;
- Product substitution and therapeutic interchangeability.
How strong is the patent estate for penicillin G benzathine?
The patent estate is weak as a blocking asset but the manufacturing position can be strong.
| Risk category |
Assessment |
| Core molecule patent |
Very weak or expired |
| New use patent |
Low relevance |
| Formulation patent |
Limited blocking value |
| Manufacturing know-how |
Moderate practical value |
| Sterile injectable capability |
High operational value |
| Regulatory exclusivity |
Low |
| Brand recognition |
Moderate |
| Supplier scarcity |
High |
| Litigation barrier |
Low |
| Generic development barrier |
Moderate to high |
For licensing or acquisition, the value proposition is more likely to reside in a validated sterile manufacturing platform, regulatory history, supply contracts and regional registrations than in patent rights.
What generic launch scenarios exist?
Scenario 1: No new U.S. entrant
The incumbent remains the principal supplier because the market is small, technically difficult and vulnerable to shortages. Prices remain controlled, but supply reliability continues to influence purchasing.
Scenario 2: One approved generic entrant
A generic supplier enters after completing suspension-equivalence work and qualifying sterile production. The entrant captures institutional and public-health contracts but may not materially reduce shortages unless it adds capacity.
Scenario 3: Multiple regional entrants
Several suppliers enter outside the United States through national approval pathways and tenders. Prices fall, but supply remains unstable if active-ingredient capacity is concentrated.
Scenario 4: New long-acting formulation
A reformulated injectable or alternative delivery system gains approval. It could compete for rheumatic fever prophylaxis and syphilis treatment if it demonstrates equivalent efficacy, acceptable injection burden and reliable supply. Regulatory and clinical-development costs would be substantially higher than for a conventional generic.
How does penicillin G benzathine compare with penicillin G procaine?
| Attribute |
Benzathine penicillin G |
Procaine penicillin G |
| Duration |
Longer depot effect |
Shorter duration |
| Typical dosing burden |
One or limited injections |
Repeated injections |
| Syphilis role |
Preferred standard for most recommended regimens |
Not interchangeable with benzathine |
| Rheumatic fever prophylaxis |
Established long-term use |
Less convenient |
| Market demand |
Larger and growing |
Smaller and more regional |
| Supply risk |
High because of concentrated supply |
High but less visible |
| Patent risk |
Low |
Low |
| Manufacturing barrier |
High |
Moderate to high |
| Commercial outlook |
Stronger |
Stable to modest |
What is the investment and licensing outlook?
Benzathine penicillin G has attractive public-health demand but limited patent monetization potential. A commercial investment case is strongest where the asset includes:
- Approved sterile injectable capacity;
- Reliable penicillin API sourcing;
- Multiple manufacturing sites;
- Government or hospital contracts;
- Registrations in shortage-prone jurisdictions;
- A differentiated prefilled syringe or delivery system;
- Evidence supporting improved adherence or reduced injection burden.
Penicillin G procaine is more suitable as a portfolio product, regional supply asset or hospital-injectable offering than as a stand-alone high-growth franchise.
Key Takeaways
- Benzathine penicillin G is the commercially stronger product because of syphilis treatment and rheumatic fever prophylaxis demand.
- Penicillin G procaine has a narrower role and weaker growth outlook.
- Both products are effectively off-patent; manufacturing and supply capacity are the main barriers.
- The FDA market is highly sensitive to shortages and supplier concentration.
- Clinical research is focused on dosing, pregnancy, congenital syphilis, adherence and delivery systems.
- A conventional generic entrant faces low patent risk but meaningful sterile-manufacturing and regulatory risk.
- The base-case market outlook for benzathine penicillin G is approximately 5% to 8% annual growth through 2030, led by public-health demand.
- Licensing value is concentrated in manufacturing capability, registrations, supply contracts and delivery technology rather than core drug patents.
FAQs
Is Bicillin L-A the same as penicillin G procaine?
No. Bicillin L-A contains benzathine penicillin G. Penicillin G procaine uses a different salt and has different pharmacokinetics, dosing and clinical uses.
Can Bicillin C-R replace Bicillin L-A for syphilis?
No. Bicillin C-R is not an appropriate substitute for Bicillin L-A in recommended syphilis treatment because it contains a different combination and dose profile (CDC, 2021).
Is penicillin G benzathine available as an oral generic?
No. Benzathine penicillin G is a depot intramuscular product. Oral penicillin formulations are not therapeutically interchangeable with it for its principal indications.
Why do shortages occur if the drug has no meaningful patent protection?
Shortages can result from concentrated manufacturing, limited sterile injectable capacity, quality-control problems, constrained API supply, demand spikes and low commercial incentives for additional suppliers.
Is there a biosimilar market for penicillin G benzathine?
No. Penicillin G benzathine is a small-molecule antibiotic, not a biologic. Competitors would generally pursue generic or national abbreviated-approval pathways rather than biosimilar approval.
References
-
Centers for Disease Control and Prevention. (2021). Sexually transmitted infections treatment guidelines, 2021. U.S. Department of Health and Human Services.
-
Centers for Disease Control and Prevention. (2024). Sexually transmitted infections surveillance, 2022. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Drug shortages: Current and resolved drug shortages and discontinuations. U.S. Department of Health and Human Services.
-
World Health Organization. (2024). Global sexually transmitted infections surveillance 2022. World Health Organization.
-
World Health Organization. (2024). Guideline for the prevention and diagnosis of rheumatic fever and rheumatic heart disease. World Health Organization.
